- KSQ-4279 is a first-in-class, potent, and selective small-molecule inhibitor of USP1, a protein that regulates DNA damage response (DDR).
- In July 2023, we entered into a worldwide license and collaboration agreement with Roche for the development and commercialization of KSQ-4279; under the collaboration, Roche has assumed all development responsibilities for KSQ-4279 (as RO7623066).
- KSQ-4279/RO7623066 is currently being studied in a Phase 1 clinical trial in patients with a variety of advanced solid tumors:
